| 1 |
34560172 | MK212, a 5-hydroxytryptamine 2C receptor agonist, reverses prepulse inhibition deficits in the medial prefrontal cortex and ventral hippocampus. | 2022 Mar 8 |
1 |
| 2 |
31968217 | Fluoxetine improves behavioural deficits induced by chronic alcohol treatment by alleviating RNA editing of 5-HT2C receptors. | 2020 Mar |
3 |
| 3 |
29548885 | Activation of 5-HT2C (but not 5-HT1A) receptors in the amygdala enhances fear-induced antinociception: Blockade with local 5-HT2C antagonist or systemic fluoxetine. | 2018 Jun |
1 |
| 4 |
27059332 | Rat exposure in mice with neuropathic pain induces fear and antinociception that is not reversed by 5-HT2C receptor activation in the dorsal periaqueductal gray. | 2016 Jul 1 |
1 |
| 5 |
26380122 | Genotype-Dependent Difference in 5-HT2C Receptor-Induced Hypolocomotion: Comparison with 5-HT2A Receptor Functional Activity. | 2015 |
2 |
| 6 |
17141810 | Activation of the brain 5-HT2C receptors causes hypolocomotion without anxiogenic-like cardiovascular adjustments in mice. | 2007 Mar |
2 |
| 7 |
17415471 | Effect of 5HT2C-receptor agonist MK-212 on blood corticosterone level and behavior in mice. | 2006 Nov |
1 |